Spots Global Cancer Trial Database for waldenström's macroglobulinemia
Every month we try and update this database with for waldenström's macroglobulinemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim | NCT04947618 | Lymphoma, Malig... | 15 Years - | Centre Hospitalier Universitaire de Nīmes | ||
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | NCT02238522 | Lymphoprolifera... Acute Myeloid L... | ZEN003365 | 18 Years - | Zenith Epigenetics | |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | NCT02238522 | Lymphoprolifera... Acute Myeloid L... | ZEN003365 | 18 Years - | Zenith Epigenetics | |
| Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma | NCT03261349 | Indolent Lympho... | Ledipasvir and ... | 20 Years - | National Taiwan University Hospital | |
| Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia | NCT01788020 | Waldenström's M... | Dexamethasone, ... Dexamethasone, ... | 18 Years - | University of Ulm | |
| Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia | NCT05952037 | Waldenstrom Mac... Waldenstrom's M... Waldenstrom's M... | BGB-11417 | 18 Years - | BeiGene | |
| A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) | NCT03053440 | Waldenström's M... | BGB-3111 Ibrutinib | 18 Years - | BeiGene | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | NCT01607892 | Hematological M... | KPT-330 | 18 Years - | Karyopharm Therapeutics Inc | |
| A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia | NCT05979948 | Waldenström's M... | Zanubrutinib Bendamustine Rituximab | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia | NCT00398710 | Waldenström's M... | Perifosine | 18 Years - | AEterna Zentaris | |
| Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | NCT01607892 | Hematological M... | KPT-330 | 18 Years - | Karyopharm Therapeutics Inc | |
| Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | NCT02165397 | Waldenström's M... | Ibrutinib Placebo Rituximab | 18 Years - | Pharmacyclics LLC. | |
| Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | NCT02165397 | Waldenström's M... | Ibrutinib Placebo Rituximab | 18 Years - | Pharmacyclics LLC. | |
| Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS | NCT03521596 | Waldenstrom Mac... | MRD and clonal ... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) | NCT03053440 | Waldenström's M... | BGB-3111 Ibrutinib | 18 Years - | BeiGene | |
| Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma | NCT03261349 | Indolent Lympho... | Ledipasvir and ... | 20 Years - | National Taiwan University Hospital | |
| R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia | NCT03697356 | Waldenström's M... | Lenalidomide, B... | 19 Years - | Kosin University Gospel Hospital | |
| Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS | NCT03521596 | Waldenstrom Mac... | MRD and clonal ... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia | NCT01788020 | Waldenström's M... | Dexamethasone, ... Dexamethasone, ... | 18 Years - | University of Ulm |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
